Drug profile · INN
doxorubicin hydrochloride liposome+irinotecan
doxorubicin hydrochloride liposome+irinotecan is an FDA-listed pharmaceutical active ingredient.
NMPA: clinical trials
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — doxorubicin hydrochloride liposome+irinotecan
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.70
Quick answer
doxorubicin hydrochloride liposome+irinotecan is an FDA-listed pharmaceutical active ingredient.
Key facts
INN doxorubicin hydrochloride liposome+irinotecan
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Frequently asked questions
What is doxorubicin hydrochloride liposome+irinotecan?
doxorubicin hydrochloride liposome+irinotecan is an FDA-listed pharmaceutical active ingredient.